Upperton Pharma Solutions has won the Pharma Contract Services Company of the Year award at the Pharma Industry Awards UK 2025, as well as being nominated as a finalist for Pharma Company of the Year.
This marks a second year of success at the Pharma Industry Awards for Upperton, with a win back in 2024 for Large Pharma Project of the Year.
Now in its third year, the Pharma Industry Awards UK are amongst the most prestigious events in the UK Pharma Calendar.
Each finalist is carefully assessed by an independent panel of experts with expertise ranging from academia to industry.
Finalists must demonstrate outstanding achievement in innovation and strategy, as well as proving a significant measurable impact in client projects.
This year's win marks a major milestone for the Nottingham-based contract development and manufacturing organisation (CDMO).
It has built a strong reputation for supporting small to medium-sized biotech companies globally.
Its work ranges from pre-clinical development to late-stage manufacturing, specialising in oral, nasal, pulmonary and parenteral dosage forms.
Nikki Whitfield, Chief Executive Officer of Upperton Pharma Solutions, said: “Winning the Pharma Contract Services of the Year is an incredible recognition of our team’s hard work and dedication."
"This award reflects the trust our clients place in us and our commitment to delivering science-led solutions that help bring medicines to patients faster.”
Categories were fiercely contested amongst leading names in pharma this year, with industry observers regarding Upperton’s win this year as an important milestone.
Upperton winning the award for Contract Services Company of the Year builds on the success at the 2024 Pharma Industry Awards UK.
Upperton won the Large Pharma Project of the Year for the construction of its 50,000 square-foot development and manufacturing facility, Trent Gateway.
The win for Upperton comes at a time when the CDMO market is set to grow exponentially with the launch of personalised medicines.
With biotech and pharmaceutical companies seeking more specialised partners to accelerate specialised therapies to market, Upperton’s flexibility and reputation for excellence have made it a trusted partner to companies in the UK and around the world.
Upperton’s Chief Scientific Officer, Richard Johnson, noted that 2025 is an exciting time for Upperton.
Work has been moving towards completion for a new sterile facility, plus Upperton received funding to support the development of an oral formulation for Adenovirus-vectored vaccines in partnership with the University of Oxford’s Pandemic Sciences Institute.